Medtronic‘s (NYSE:MDT) today released data from a retrospective analysis of patients with its Reactive ATP therapy, touting slowed atrial fibrillation progression for individuals with implanted cardiac devices.
Data came from a retrospective analysis of approximately 8,800 patients and was presented at the EHRA Europace-Cardiostim 2017 meeting, Fridley, Minn.-based Medtronic said.
“Atrial fibrillation can be a debilitating disease that imposes a significant burden upon the entire healthcare community – impacting patients, caregivers, providers and costs of care – especially as the disease progresses. These are the first real-world data on the clinical impact of Reactive ATP therapy and the first in patients with ICDs and CRT devices. These data have important implications for all device patients because of the high prevalence of AF and the correlation of disease progression to worsened patient outcomes,” Dr. Giuseppe Boriani of Italy’s University of Modena and Reggio Emilia said in a press release.
Medtronic’s Reactive ATP is a pacing therapy designed to repeatedly send pacing pulses to the atria during abnormally fast rhythms to restore normal rhythm and slow the progression of AF. In the study, device data was collected from 8,798 patients on the company’s CareLink remote monitoring system.
Results indicated that the Reactive ATP therapy was associated with a statistically significant decrease in AF events compared to the control group, with a 38% reduction in persistent AF events. Benefits were observed across patient age, sex and device type, Medtronic reported.
“Physicians have been asking how the CareLink Network data can be leveraged to gain real-world insights into the benefits of our therapies. This study does exactly that. It helps us understand how Reactive ATP impacts the burden of persistent atrial fibrillation in a larger and more varied group of patients than we might normally be able to study within the constraints of a controlled trial,” cardiac rhythm and heart failure division chief medical officer Dr. Rob Kowal said in a prepared statement.
Last week, Medtronic said its nano-sized Micra pacemaker will be heading into space as part of a Nebraska high school student’s science project.
